The long-awaited AZURE Trial – The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests That the Benefits of Combining Zoledronic Acid with Adjuvant Endocrine Therapy Persist Long after Completion of Therapy – was presented today at the meeting.
Highlighted in the video is expert commentary from leaders in breast cancer research including:
• Robert Coleman, MD, Vice Chair, Clinical Research, Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center
• Sharon Giordano, MD, MPH, Associate Professor of Medicine and Internist, Department of Breast Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center
• Michael Gnant, MD, Professor of Surgery, Medical University of Vienna
For more information from SABCS 2010, please click here: SABCS 2010.